Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers
Standard
Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers. / Melling, Nathaniel; Grass, Julia; Reeh, Matthias; Tachezy, Michael; Blessmann, Marco; Izbicki, Jakob R; Grupp, Katharina.
in: J CANCER RES CLIN, Jahrgang 149, Nr. 10, 08.2023, S. 7579-7585.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers
AU - Melling, Nathaniel
AU - Grass, Julia
AU - Reeh, Matthias
AU - Tachezy, Michael
AU - Blessmann, Marco
AU - Izbicki, Jakob R
AU - Grupp, Katharina
N1 - © 2023. The Author(s).
PY - 2023/8
Y1 - 2023/8
N2 - BACKGROUND: Prolyl hydroxylase 1 (PHD1) is a prognostic marker in several cancers.AIMS AND SCOPES: This study was undertaken to elucidate the clinical relevance of PHD1 in colorectal cancer (CRC) prognosis.MATERIALS AND METHODS: We compared PHD1 expression on a tissue microarray (TMA) containing samples from 1800 CRCs with corresponding clinicopathological tumor variables and patient survival.RESULTS: While PHD1 staining was always high in benign colorectal epithelium, high PHD1 staining was detectable in only 71.8% of CRCs. Low PHD1 staining was associated with advanced tumor stage (p = 0.0101) and shortened overall survival in CRC patients (p = 0.0011). In a multivariable analysis including tumor stage, histological type and PHD1 staining revealed tumor stage and histological type (p < 0.0001 each), but also PHD1 staining (p = 0.0202) to be independent prognostic markers for CRC.CONCLUSIONS: In our cohort, loss of PHD1 expression independently identified a subset of CRC patients with poor overall survival and might, thus, be a promising prognostic marker. PHD1 targeting may even allow for specific therapeutic approaches for these patients.
AB - BACKGROUND: Prolyl hydroxylase 1 (PHD1) is a prognostic marker in several cancers.AIMS AND SCOPES: This study was undertaken to elucidate the clinical relevance of PHD1 in colorectal cancer (CRC) prognosis.MATERIALS AND METHODS: We compared PHD1 expression on a tissue microarray (TMA) containing samples from 1800 CRCs with corresponding clinicopathological tumor variables and patient survival.RESULTS: While PHD1 staining was always high in benign colorectal epithelium, high PHD1 staining was detectable in only 71.8% of CRCs. Low PHD1 staining was associated with advanced tumor stage (p = 0.0101) and shortened overall survival in CRC patients (p = 0.0011). In a multivariable analysis including tumor stage, histological type and PHD1 staining revealed tumor stage and histological type (p < 0.0001 each), but also PHD1 staining (p = 0.0202) to be independent prognostic markers for CRC.CONCLUSIONS: In our cohort, loss of PHD1 expression independently identified a subset of CRC patients with poor overall survival and might, thus, be a promising prognostic marker. PHD1 targeting may even allow for specific therapeutic approaches for these patients.
KW - Humans
KW - Prolyl Hydroxylases
KW - Prognosis
KW - Colorectal Neoplasms/pathology
KW - Biomarkers, Tumor/metabolism
U2 - 10.1007/s00432-023-04717-y
DO - 10.1007/s00432-023-04717-y
M3 - SCORING: Journal article
C2 - 36976352
VL - 149
SP - 7579
EP - 7585
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 10
ER -